Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Benefits of reviewing pancreatic function in children with cystic fibrosis
  • Rachael Marpole,
  • Andrew Wilson
Rachael Marpole
Perth Children's Hospital

Corresponding Author:[email protected]

Author Profile
Andrew Wilson
Perth Children's Hospital
Author Profile

Abstract

Background: Cystic fibrosis is a common cause of pancreatic exocrine insufficiency. Clinically pancreatic insufficiency is treated as a permanent problem. However, new cystic fibrosis transmembrane conductance regulator (CFTR) protein modulator therapies, like ivacaftor, can change pancreatic function in children. Also, children with residual CFTR function mutations may be pancreatic insufficient in infancy and spontaneously become pancreatic sufficient. Aims: To evaluate the benefit of reviewing pancreatic function, testing and diagnosis, of a cohort and repeat testing to patients with the potential to change function. Methods: all children with cystic fibrosis managed at Perth Children’s Hospital at the end of 2019 were reviewed for pancreatic function testing at diagnosis, genotype and current modulator and pancreatic enzyme replacement therapy use. Children with the potential to change pancreatic function were offered repeat testing. Results: 204 children were included. 11 children were prescribed ivacaftor and four of these became pancreatic sufficient. Five children with a residual CFTR function mutation were pancreatic insufficient at diagnosis. Four became pancreatic sufficient. Conclusion: there is benefit in re-evaluating pancreatic function in children with cystic fibrosis regularly, especially if on ivacaftor or pancreatic insufficient with a residual CFTR function mutation.
03 Feb 2022Submitted to Pediatric Pulmonology
03 Feb 2022Submission Checks Completed
03 Feb 2022Assigned to Editor
06 Feb 2022Review(s) Completed, Editorial Evaluation Pending
06 Feb 2022Editorial Decision: Revise Minor
21 Feb 20221st Revision Received
21 Feb 2022Submission Checks Completed
21 Feb 2022Assigned to Editor
24 Feb 2022Review(s) Completed, Editorial Evaluation Pending
24 Feb 2022Editorial Decision: Revise Minor
27 Feb 20222nd Revision Received
28 Feb 2022Submission Checks Completed
28 Feb 2022Assigned to Editor
02 Mar 2022Review(s) Completed, Editorial Evaluation Pending
05 Mar 2022Editorial Decision: Accept
08 Mar 2022Published in Pediatric Pulmonology. 10.1002/ppul.25884